Department of Internal Medicine, Division of Dermatology, Dell Medical School at the University of Texas at Austin, 313 E 12th St, Suite 103, Austin, TX, 78701, USA.
Department of Dermatology, Johns Hopkins Medicine, Baltimore, USA.
Arch Dermatol Res. 2023 Oct;315(8):2283-2288. doi: 10.1007/s00403-023-02595-5. Epub 2023 Mar 25.
There is a paucity of data examining the psychosocial factors relevant to depigmentation therapy, an irreversible treatment for vitiligo. This study explores patients' perspective and experience while undergoing depigmentation therapy and quality-of-life effects of such therapy.
An online instrument assessing the impact of depigmentation therapy on various psychosocial variables and including the validated Dermatology Life Quality Index (DLQI) were administered to two groups of participants with vitiligo: (1) those who are currently undergoing or have completed depigmentation therapy and (2) those with vitiligo who have not undergone depigmentation therapy but had considered it. Data were collected on psychosocial factors such as length of time until depigmentation therapy was offered, duration, financial burden, level of satisfaction, impact on life activities, and challenges faced during and after depigmentation therapy. DLQI scores were also measured.
Thirty-five vitiligo patients who did not undergo depigmentation and 42 patients who did undergo depigmentation therapy were included in the study. Baseline characteristics were comparable between groups. Mean DLQI was higher for patients who did not undergo depigmentation than for those who underwent depigmentation (10.2 versus 5.3, p = 0.002), indicating worse quality-of-life in those not depigmenting. Patients who underwent depigmentation reported significantly less discomfort in various social situations after undergoing depigmentation therapy compared to how they felt before undergoing therapy and reported significantly less discomfort in these situations than patients who did not undergo depigmentation therapy.
Despite potential challenges, depigmentation therapy appears to augment quality-of-life across various domains in individuals with vitiligo.
目前针对白癜风不可逆治疗方法——脱色疗法，相关心理社会因素的数据研究较为匮乏。本研究旨在探讨患者接受脱色疗法的过程中的看法和体验，以及该疗法对生活质量的影响。
本研究使用在线工具评估脱色疗法对各种心理社会变量的影响，其中包括经过验证的皮肤病生活质量指数（DLQI），并将其应用于两组白癜风患者：（1）正在接受或已完成脱色疗法的患者，以及（2）未接受但考虑过接受脱色疗法的患者。收集的资料包括接受脱色疗法的时间长短、疗程、经济负担、满意度水平、对生活活动的影响以及在接受和完成脱色疗法期间和之后所面临的挑战等心理社会因素。还测量了 DLQI 评分。
本研究共纳入 35 名未接受脱色治疗和 42 名接受脱色治疗的白癜风患者。两组患者的基线特征无显著差异。未接受脱色治疗的患者的平均 DLQI 评分高于接受脱色治疗的患者（10.2 比 5.3，p=0.002），表明未脱色治疗的患者生活质量更差。与治疗前相比，接受脱色治疗的患者在接受治疗后在各种社交情况下感到的不适明显减少，并且与未接受脱色治疗的患者相比，在这些情况下感到的不适明显减少。
尽管存在潜在的挑战，但脱色疗法似乎可改善白癜风患者各个领域的生活质量。
